Criticisms of drugs in early development for the treatment of depression

What can be improved?

Sheng Min Wang, Changsu Han, Chi Un Pae

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Major depressive disorder (MDD) is a common and debilitating mental illness, which leads to serious functional impairment in patients, and treatment-wise, there are currently a number of different classes of antidepressants already on the market. However, emerging evidence from numerous clinical trials has confirmed that there is still an unmet need for antidepressant efficacy in terms of response and remission. Approximately only 30% of patients with MDD may remit after adequate treatment with antidepressants in clinical practice. The drawbacks of the currently available antidepressants also include inadequate overall efficacy, safety issues and the lag prior to onset of clinical improvement. The need for new agents with novel mechanisms of action has led to the development of several newer antidepressants including vilazodone, edivoxetine, ketamine, atomoxetine and vortioxetine, which have been approved for the treatment of MDD. However, the efficacy and safety of these next-generation antidepressants, in clinical trials, are still unsatisfactory. This paper provides a brief updated overview of the progress and critical limitations in the development of novel antidepressants.

Original languageEnglish
Pages (from-to)445-453
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume24
Issue number4
DOIs
Publication statusPublished - 2015 Apr 1

Fingerprint

Antidepressive Agents
Depression
Pharmaceutical Preparations
Major Depressive Disorder
alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol
Therapeutics
Clinical Trials
Safety
Ketamine

Keywords

  • Monoamine
  • Novel antidepressant
  • Receptor
  • Reuptake inhibition
  • Transporter

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Criticisms of drugs in early development for the treatment of depression : What can be improved? / Wang, Sheng Min; Han, Changsu; Pae, Chi Un.

In: Expert Opinion on Investigational Drugs, Vol. 24, No. 4, 01.04.2015, p. 445-453.

Research output: Contribution to journalReview article

@article{491c351bcac7413fbfa041690fdf9eca,
title = "Criticisms of drugs in early development for the treatment of depression: What can be improved?",
abstract = "Major depressive disorder (MDD) is a common and debilitating mental illness, which leads to serious functional impairment in patients, and treatment-wise, there are currently a number of different classes of antidepressants already on the market. However, emerging evidence from numerous clinical trials has confirmed that there is still an unmet need for antidepressant efficacy in terms of response and remission. Approximately only 30{\%} of patients with MDD may remit after adequate treatment with antidepressants in clinical practice. The drawbacks of the currently available antidepressants also include inadequate overall efficacy, safety issues and the lag prior to onset of clinical improvement. The need for new agents with novel mechanisms of action has led to the development of several newer antidepressants including vilazodone, edivoxetine, ketamine, atomoxetine and vortioxetine, which have been approved for the treatment of MDD. However, the efficacy and safety of these next-generation antidepressants, in clinical trials, are still unsatisfactory. This paper provides a brief updated overview of the progress and critical limitations in the development of novel antidepressants.",
keywords = "Monoamine, Novel antidepressant, Receptor, Reuptake inhibition, Transporter",
author = "Wang, {Sheng Min} and Changsu Han and Pae, {Chi Un}",
year = "2015",
month = "4",
day = "1",
doi = "10.1517/13543784.2014.985784",
language = "English",
volume = "24",
pages = "445--453",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Criticisms of drugs in early development for the treatment of depression

T2 - What can be improved?

AU - Wang, Sheng Min

AU - Han, Changsu

AU - Pae, Chi Un

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Major depressive disorder (MDD) is a common and debilitating mental illness, which leads to serious functional impairment in patients, and treatment-wise, there are currently a number of different classes of antidepressants already on the market. However, emerging evidence from numerous clinical trials has confirmed that there is still an unmet need for antidepressant efficacy in terms of response and remission. Approximately only 30% of patients with MDD may remit after adequate treatment with antidepressants in clinical practice. The drawbacks of the currently available antidepressants also include inadequate overall efficacy, safety issues and the lag prior to onset of clinical improvement. The need for new agents with novel mechanisms of action has led to the development of several newer antidepressants including vilazodone, edivoxetine, ketamine, atomoxetine and vortioxetine, which have been approved for the treatment of MDD. However, the efficacy and safety of these next-generation antidepressants, in clinical trials, are still unsatisfactory. This paper provides a brief updated overview of the progress and critical limitations in the development of novel antidepressants.

AB - Major depressive disorder (MDD) is a common and debilitating mental illness, which leads to serious functional impairment in patients, and treatment-wise, there are currently a number of different classes of antidepressants already on the market. However, emerging evidence from numerous clinical trials has confirmed that there is still an unmet need for antidepressant efficacy in terms of response and remission. Approximately only 30% of patients with MDD may remit after adequate treatment with antidepressants in clinical practice. The drawbacks of the currently available antidepressants also include inadequate overall efficacy, safety issues and the lag prior to onset of clinical improvement. The need for new agents with novel mechanisms of action has led to the development of several newer antidepressants including vilazodone, edivoxetine, ketamine, atomoxetine and vortioxetine, which have been approved for the treatment of MDD. However, the efficacy and safety of these next-generation antidepressants, in clinical trials, are still unsatisfactory. This paper provides a brief updated overview of the progress and critical limitations in the development of novel antidepressants.

KW - Monoamine

KW - Novel antidepressant

KW - Receptor

KW - Reuptake inhibition

KW - Transporter

UR - http://www.scopus.com/inward/record.url?scp=84924713307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924713307&partnerID=8YFLogxK

U2 - 10.1517/13543784.2014.985784

DO - 10.1517/13543784.2014.985784

M3 - Review article

VL - 24

SP - 445

EP - 453

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 4

ER -